clinical trial · NCT07104032
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co., Ltd.·phase3·recruiting·n = 132
Relapsed/Refractory Primary Central Nervous System LymphomaTirabrutinibRituximabTemozolomide
brief summary
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
started
Jun 12, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2029
last updated
Jun 16, 2026
official title
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol